Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors

Hannah K. Knudsen; Lori J. Ducharme; Paul M. Roman

doi:10.1016/j.jsat.2006.03.013

Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors

Hannah K. Knudsen
, Lori J. Ducharme
, Paul M. Roman

Behavioral Science

Research output: Contribution to journal › Article › peer-review

112 Scopus citations

Abstract

The recent approval of buprenorphine for the treatment of opiate dependence offers an opportunity to analyze innovation adoption in community-based treatment. Using data collected from national samples of 299 privately funded and 277 publicly funded treatment centers, this research examines buprenorphine adoption using baseline data collected between 2002 and 2004 as well as follow-up data collected 12 months later. Private centers were significantly more likely than public centers to report current use of buprenorphine. The baseline data indicated that early adoption was positively associated with center accreditation, physician services, availability of detoxification services, current use of naltrexone, and the percentage of opiate-dependent clients. Multivariate analyses of follow-up data suggest that adoption was greater in accredited centers, for-profit facilities, organizations offering detoxification services, and naltrexone-using centers. Future research should continue to monitor the extent to which buprenorphine is adopted in these settings.

Original language	English
Pages (from-to)	363-373
Number of pages	11
Journal	Journal of Substance Abuse Treatment
Volume	30
Issue number	4
DOIs	https://doi.org/10.1016/j.jsat.2006.03.013
State	Published - Jun 2006

Bibliographical note

Funding Information:
The authors gratefully acknowledge the research support of the National Institute on Drug Abuse (grant nos. R01DA14482 and R01DA13110).

Funding

The authors gratefully acknowledge the research support of the National Institute on Drug Abuse (grant nos. R01DA14482 and R01DA13110).

Funders	Funder number
National Institute on Drug Abuse	R01DA013110, R01DA14482

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adoption of innovations
Buprenorphine
Health services research

ASJC Scopus subject areas

Psychiatric Mental Health
Medicine (miscellaneous)
Clinical Psychology
Psychiatry and Mental health

Access to Document

10.1016/j.jsat.2006.03.013

Cite this

@article{a00b3bf5cea64ca39d05a4cf7a70f00a,

title = "Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors",

abstract = "The recent approval of buprenorphine for the treatment of opiate dependence offers an opportunity to analyze innovation adoption in community-based treatment. Using data collected from national samples of 299 privately funded and 277 publicly funded treatment centers, this research examines buprenorphine adoption using baseline data collected between 2002 and 2004 as well as follow-up data collected 12 months later. Private centers were significantly more likely than public centers to report current use of buprenorphine. The baseline data indicated that early adoption was positively associated with center accreditation, physician services, availability of detoxification services, current use of naltrexone, and the percentage of opiate-dependent clients. Multivariate analyses of follow-up data suggest that adoption was greater in accredited centers, for-profit facilities, organizations offering detoxification services, and naltrexone-using centers. Future research should continue to monitor the extent to which buprenorphine is adopted in these settings.",

keywords = "Adoption of innovations, Buprenorphine, Health services research",

author = "Knudsen, \{Hannah K.\} and Ducharme, \{Lori J.\} and Roman, \{Paul M.\}",

note = "Funding Information: The authors gratefully acknowledge the research support of the National Institute on Drug Abuse (grant nos. R01DA14482 and R01DA13110).",

year = "2006",

month = jun,

doi = "10.1016/j.jsat.2006.03.013",

language = "English",

volume = "30",

pages = "363--373",

number = "4",

}

TY - JOUR

T1 - Early adoption of buprenorphine in substance abuse treatment centers

T2 - Data from the private and public sectors

AU - Knudsen, Hannah K.

AU - Ducharme, Lori J.

AU - Roman, Paul M.

N1 - Funding Information: The authors gratefully acknowledge the research support of the National Institute on Drug Abuse (grant nos. R01DA14482 and R01DA13110).

PY - 2006/6

Y1 - 2006/6

N2 - The recent approval of buprenorphine for the treatment of opiate dependence offers an opportunity to analyze innovation adoption in community-based treatment. Using data collected from national samples of 299 privately funded and 277 publicly funded treatment centers, this research examines buprenorphine adoption using baseline data collected between 2002 and 2004 as well as follow-up data collected 12 months later. Private centers were significantly more likely than public centers to report current use of buprenorphine. The baseline data indicated that early adoption was positively associated with center accreditation, physician services, availability of detoxification services, current use of naltrexone, and the percentage of opiate-dependent clients. Multivariate analyses of follow-up data suggest that adoption was greater in accredited centers, for-profit facilities, organizations offering detoxification services, and naltrexone-using centers. Future research should continue to monitor the extent to which buprenorphine is adopted in these settings.

AB - The recent approval of buprenorphine for the treatment of opiate dependence offers an opportunity to analyze innovation adoption in community-based treatment. Using data collected from national samples of 299 privately funded and 277 publicly funded treatment centers, this research examines buprenorphine adoption using baseline data collected between 2002 and 2004 as well as follow-up data collected 12 months later. Private centers were significantly more likely than public centers to report current use of buprenorphine. The baseline data indicated that early adoption was positively associated with center accreditation, physician services, availability of detoxification services, current use of naltrexone, and the percentage of opiate-dependent clients. Multivariate analyses of follow-up data suggest that adoption was greater in accredited centers, for-profit facilities, organizations offering detoxification services, and naltrexone-using centers. Future research should continue to monitor the extent to which buprenorphine is adopted in these settings.

KW - Adoption of innovations

KW - Buprenorphine

KW - Health services research

UR - https://www.scopus.com/pages/publications/33646563473

UR - https://www.scopus.com/pages/publications/33646563473#tab=citedBy

U2 - 10.1016/j.jsat.2006.03.013

DO - 10.1016/j.jsat.2006.03.013

M3 - Article

C2 - 16716852

AN - SCOPUS:33646563473

SN - 0740-5472

VL - 30

SP - 363

EP - 373

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

IS - 4

ER -

Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this